Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Movement Termination of Slow-Wave Sleep-A Potential Biomarker

Y. Höller, SG. Eyjólfsdóttir, M. Rusiňák, LS. Guðmundsson, E. Trinka

. 2024 ; 14 (5) : . [pub] 20240513

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012800

The duration of slow-wave sleep (SWS) is related to the reported sleep quality and to the important variables of mental and physical health. The internal cues to end an episode of SWS are poorly understood. One such internal cue is the initiation of a body movement, which is detectable as electromyographic (EMG) activity in sleep-electroencephalography (EEG). In the present study, we characterized the termination of SWS episodes by movement to explore its potential as a biomarker. To this end, we characterized the relation between the occurrence of SWS termination by movement and individual characteristics (age, sex), SWS duration and spectral content, chronotype, depression, medication, overnight memory performance, and, as a potential neurological application, epilepsy. We analyzed 94 full-night EEG-EMG recordings (75/94 had confirmed epilepsy) in the video-EEG monitoring unit of the EpiCARE Centre Salzburg, Austria. Segments of SWS were counted and rated for their termination by movement or not through the visual inspection of continuous EEG and EMG recordings. Multiple linear regression was used to predict the number of SWS episodes that ended with movement by depression, chronotype, type of epilepsy (focal, generalized, no epilepsy, unclear), medication, gender, total duration of SWS, occurrence of seizures during the night, occurrence of tonic-clonic seizures during the night, and SWS frequency spectra. Furthermore, we assessed whether SWS movement termination was related to overnight memory retention. According to multiple linear regression, patients with overall longer SWS experienced more SWS episodes that ended with movement (t = 5.64; p = 0.001). No other variable was related to the proportion of SWS that ended with movement, including no epilepsy-related variable. A small sample (n = 4) of patients taking Sertraline experienced no SWS that ended with movement, which was significant compared to all other patients (t = 8.00; p < 0.001) and to n = 35 patients who did not take any medication (t = 4.22; p < 0.001). While this result was based on a small subsample and must be interpreted with caution, it warrants replication in a larger sample with and without seizures to further elucidate the role of the movement termination of SWS and its potential to serve as a biomarker for sleep continuity and for medication effects on sleep.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012800
003      
CZ-PrNML
005      
20240726151346.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/brainsci14050493 $2 doi
035    __
$a (PubMed)38790471
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Höller, Yvonne $u Faculty of Psychology, University of Akureyri, 600 Akureyri, Iceland $1 https://orcid.org/0000000217278557
245    10
$a Movement Termination of Slow-Wave Sleep-A Potential Biomarker / $c Y. Höller, SG. Eyjólfsdóttir, M. Rusiňák, LS. Guðmundsson, E. Trinka
520    9_
$a The duration of slow-wave sleep (SWS) is related to the reported sleep quality and to the important variables of mental and physical health. The internal cues to end an episode of SWS are poorly understood. One such internal cue is the initiation of a body movement, which is detectable as electromyographic (EMG) activity in sleep-electroencephalography (EEG). In the present study, we characterized the termination of SWS episodes by movement to explore its potential as a biomarker. To this end, we characterized the relation between the occurrence of SWS termination by movement and individual characteristics (age, sex), SWS duration and spectral content, chronotype, depression, medication, overnight memory performance, and, as a potential neurological application, epilepsy. We analyzed 94 full-night EEG-EMG recordings (75/94 had confirmed epilepsy) in the video-EEG monitoring unit of the EpiCARE Centre Salzburg, Austria. Segments of SWS were counted and rated for their termination by movement or not through the visual inspection of continuous EEG and EMG recordings. Multiple linear regression was used to predict the number of SWS episodes that ended with movement by depression, chronotype, type of epilepsy (focal, generalized, no epilepsy, unclear), medication, gender, total duration of SWS, occurrence of seizures during the night, occurrence of tonic-clonic seizures during the night, and SWS frequency spectra. Furthermore, we assessed whether SWS movement termination was related to overnight memory retention. According to multiple linear regression, patients with overall longer SWS experienced more SWS episodes that ended with movement (t = 5.64; p = 0.001). No other variable was related to the proportion of SWS that ended with movement, including no epilepsy-related variable. A small sample (n = 4) of patients taking Sertraline experienced no SWS that ended with movement, which was significant compared to all other patients (t = 8.00; p < 0.001) and to n = 35 patients who did not take any medication (t = 4.22; p < 0.001). While this result was based on a small subsample and must be interpreted with caution, it warrants replication in a larger sample with and without seizures to further elucidate the role of the movement termination of SWS and its potential to serve as a biomarker for sleep continuity and for medication effects on sleep.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Eyjólfsdóttir, Stefanía Guðrún $u Faculty of Psychology, University of Akureyri, 600 Akureyri, Iceland
700    1_
$a Rusiňák, Matej $u Faculty of Psychology, University of Akureyri, 600 Akureyri, Iceland $u Faculty of Social Studies, Masaryk University, 601 77 Brno, Czech Republic
700    1_
$a Guðmundsson, Lárus Steinþór $u Faculty of Pharmaceutical Sciences, University of Iceland, 102 Reykjavík, Iceland $1 https://orcid.org/0000000346601111
700    1_
$a Trinka, Eugen $u Department of Neurology, Neurointensive Care and Neurorehabilitation, Christian-Doppler University Hospital, Paracelsus Medical University, Centre for Neuroscience Salzburg, Member of the European Reference Network, EpiCARE, 5020 Salzburg, Austria $u Neuroscience Institute, Christian-Doppler University Hospital, Centre for Cognitive Neuroscience, 5020 Salzburg, Austria
773    0_
$w MED00198694 $t Brain sciences $x 2076-3425 $g Roč. 14, č. 5 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38790471 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151339 $b ABA008
999    __
$a ok $b bmc $g 2125478 $s 1224663
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 14 $c 5 $e 20240513 $i 2076-3425 $m Brain sciences $n Brain Sci $x MED00198694
LZP    __
$a Pubmed-20240723

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...